Summary
Eli Lilly and Company (LLY) reported solid financial results for the quarter and six months ended June 30, 2019. Revenue saw a modest increase year-over-year, driven by volume growth, though partially offset by pricing pressures and foreign exchange rates. A significant highlight was the substantial gain recognized from the disposition of Elanco Animal Health, which significantly boosted net income and earnings per share for the six-month period. The company continued to invest in its robust R&D pipeline, with increased expenses reflecting development for late-stage assets and recently launched products. Looking ahead, Lilly reaffirmed its full-year 2019 financial expectations, anticipating revenue between $22.0 billion and $22.5 billion and EPS in the range of $8.58 to $8.68. The company remains focused on driving growth through key products like Trulicity, Taltz, Jardiance, and Basaglar, while managing the impact of patent expirations on older products and navigating a complex regulatory and pricing environment, particularly in the U.S. The acquisition of Loxo Oncology in February 2019 represents a strategic investment to strengthen its pipeline with promising investigational medicines.
Financial Highlights
53 data points| Revenue | $5.64B |
| Cost of Revenue | $1.12B |
| Gross Profit | $4.51B |
| R&D Expenses | $1.40B |
| SG&A Expenses | $1.59B |
| Operating Expenses | $2.99B |
| Interest Expense | $110.90M |
| Net Income | $1.33B |
| EPS (Basic) | $1.44 |
| EPS (Diluted) | $1.44 |
| Shares Outstanding (Basic) | 920.80M |
| Shares Outstanding (Diluted) | 924.60M |
Key Highlights
- 1Revenue increased by 1% to $5.64 billion for the three months ended June 30, 2019, compared to $5.59 billion in the prior year period.
- 2Net income for the six months ended June 30, 2019, was significantly impacted by a $3.7 billion gain from the disposition of Elanco Animal Health, resulting in a net income of $5.57 billion compared to $957.5 million in the prior year period.
- 3Diluted earnings per share from continuing operations were $1.44 for the three months ended June 30, 2019, up from a loss of $0.22 in the prior year period.
- 4Research and development expenses increased by 10% to $1.40 billion for the quarter and 11% to $2.63 billion for the six months, reflecting investments in late-stage pipeline assets.
- 5The company reaffirmed its full-year 2019 revenue guidance of $22.0 billion to $22.5 billion and EPS guidance of $8.58 to $8.68.
- 6The acquisition of Loxo Oncology for $6.92 billion in February 2019 adds key investigational medicines to Lilly's pipeline.
- 7The company is actively managing patent expirations for key products like Cialis and Forteo, anticipating revenue erosion and preparing for generic competition.